We are thrilled to share the exciting news that as of November 2024, people in British Columbia with HAE Type I & II now have access to ORLADEYO®

From November 7 - 9, two Board members, Michelle Cooper (President) and Kim Speiss (Reg Director, Central), along with staff, Daphne Dumbrille, were fortunate to attend the Canadian

HAE Canada's leadership team attended the inspiring Global Leadership Workshop: Navigating the Future hosted by HAE International in Copenhagen, Denmark, from October 4-5. Two days were filled with

The Canadian/International HAE Guidelines have been developed to ensure that Canadians with HAE receive relevant and up-to-date care. Since the last Guidelines were released back in 2019, new

Today, BioCryst Pharmaceuticals, announced it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the oral, once-daily treatment ORLADEYO® (berotralstat), which is approved in Canada for the

We are delighted to announce that following months of dedicated brainstorming and strategizing, the HAE Canada Board of Directors, along with the HAE Canada staff, have successfully crafted

Each year, before have day 🙂 on May 16th, HAE International organizes the HAE Global Activity Challenge as a focus for activities to raise HAE awareness amongst the

We want to send a MASSIVE THANK YOU to our friends from the CN Tower / Tour CN for helping make HAE Day 2024 so special by honouring

The current HAEC Five Year Strategic Plan ends July 2024, so the Board of Directors and staff have been meeting over the past few months to work on

The HAE Canada Board of Directors and staff are currently working with Heather Dow (Events and Management Plus) to develop our next Five Year Strategic Plan. We have